On July 2, a working meeting between the Governor of the Bryansk Region Alexander Bogomaz and the Director General of the Federal State Unitary Enterprise Moscow State Endocrine Plant Mikhail Fonarev took place in Bryansk. The chairman of the regional Duma Vladimir Popkov also took part in the meeting.
Currently the FSUE Moscow Endocrine Plant, together with the Ministry of Industry and Trade of the Russian Federation, carries out activities to create the production of active pharmaceutical ingredients on the basis of the property complex of the object on chemical weapons destruction facility in the Pochep city.
The specified project is aimed at ensuring of national drug safety of the Russian Federation. At this, the development of the facility for the production of active pharmaceutical ingredients will require considerable financial investments and time.
The details of the implementation of this investment project, the possibility of provision of the Enterprise with regional benefits and preferences that would allow to reduce the financial and tax burden for maintaining of the facility until it reaches full production capacity were discussed at the meeting.
About 70% of the active pharmaceutical ingredients from which domestic drugs are made are imported. The dependence of the Russian pharmaceutical industry on the import of ingredients, including from countries initiating sanctions against Russia, threatens the country's national security.
The essence of the investment project is to create a modern domestic enterprise for the production of active pharmaceutical ingredients of centrally-acting analgesics and other active pharmaceutical ingredients in Russia from domestic raw materials for the purpose of import substitution.
The production will provide the FSUE Moscow Endocrine Plant with active pharmaceutical ingredients for the purpose of the subsequent release of drugs, including socially significant ones, of a full cycle for sale at the domestic and foreign markets. In addition, it is planned to sell manufactured ingredients to other enterprises of the domestic pharmaceutical industry.
Comment type is not specified in the component properties.